Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human TIL therapy CC-38 in metastatic colorectal or prostate cancer
2025-521227-70-00Phase 2Authorised
- Sponsor
- CuraCell Holding AB
- Start
- Jul 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CC-38 in colorectal cancer (CRC) and prostate cancer (PCa), sponsored by CuraCell Holding AB. Primary endpoints: Incidence of treatment emergent adverse events and grade ≥3 adverse events and Feasibility of repeated TIL administrations. Planned start Jul 2025; status: authorised.
02
Drugs
CC-38
03
Conditions
colorectal cancer (CRC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-521227-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521227-70-00.